Novo Nordisk’s first DTC ad for Rybelsus shows an animated world that looks a lot better than the real one currently does. But the sunny cartoon world wasn’t Novo’s original plan.
When COVID-19 nixed all company travel, major production cities in California and New York shut down. The Danish drugmaker suddenly faced the challenge of how to launch a drug during a pandemic.
“As we started to explore (options), animation came to the forefront,” Ed Cinca, vice president of Novo Nordisk’s GLP-1 portfolio, said. “I think it turned out better than we ever imagined.”
While the goal for the launch was always to stand out in the crowded diabetes DTC space, animation was never on the table before the pandemic. The reimagined 90-second spot, titled “Wake Up,” features eye-catching animation of people all around the country having a great time. It’s accompanied by a hip, punk version of “You Are My Sunshine.”
Visuals aside, the animation serves an even more important purpose, Cinca pointed out.
“What’s center to the spot is demonstrating that this is the first and only oral GLP-1, and it works in a unique way,” he said. “What really is great about the animation is that it affords us the opportunity to be very clear and explicit about how it works in three ways.”
Cinca also wants people to see the ad as a form of hope.
“I think that’s what people really need right now, regardless of their situation, but particularly for those who are suffering with Type 2 diabetes,” he said. “(They) not only have the burden of the worry that is Type 2, but also the realities of the stresses that COVID places on it.”
Rybelsus nabbed FDA approval in September 2019 and shares the same active ingredient as Novo’s Ozempic. That drug, a weekly injectable, scored an FDA green light in December 2017 and has since soared to blockbuster status.
With Rybelsus, Novo is targeting patients who are newly diagnosed as well as patients looking for other options in managing blood sugar and weight.
In the first half this year, Rybelsus generated $92 million, beating analysts’ expectations. Meanwhile, Ozempic’s sales of $1.5 billion during the same time period made it Novo Nordisk’s top seller. The pandemic boosted overall sales due to insulin stocking, but that bump was tempered by fewer patients starting treatment, the company reported.
By: Sharon Klahr Coey
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
